Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen

D. Chhabra, A. Alvarado, P. Dalal, J. Leventhal, C. Wang, N. Sustento-Reodica, N. Najafian, A. Skaro, J. Levitsky, Valeria Mas, L. Gallon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Traditionally, chronic calcineurin inhibitor (CNI) nephrotoxicity has been considered to be one of the main nonimmune mechanisms causing chronic renal allograft dysfunction. CNI minimization and withdrawal strategies have yielded inconsistent results. Few studies address the feasibility of CNI elimination in a prednisone-free regimen. We report a prospective, randomized trial in 200 patients evaluating the impact on renal function and incidence of acute rejection after conversion from tacrolimus (Tac) to sirolimus (SRL). Patients with recent (<3 months) acute rejection episodes or with >0.5 g/day of proteinuria were excluded. All were induced with alemtuzumab, underwent rapid steroid elimination and were maintained on mycophenolate mofetil and Tac. At 12 months posttransplant, patients were randomized 2:1 to SRL (n = 123) or maintained on Tac (n = 64). Mean follow-up was 41.1 ± 15.8 months in the SRL group and 40.7 ± 14.4 months in the Tac group. Biopsy-proven acute rejection at 24 months postrandomization was similar between the groups. Patient survival, graft survival and estimated GFR were also not statistically different. Our study demonstrates that in a prednisone-free immunosuppressive regimen, conversion from Tac to SRL at 12 months posttransplantation is not associated with increased rates of acute rejection and graft loss. However, despite CNI elimination, renal allograft function is equally maintained in both groups.

Original languageEnglish (US)
Pages (from-to)2902-2911
Number of pages10
JournalAmerican Journal of Transplantation
Volume13
Issue number11
DOIs
StatePublished - Nov 1 2013

Fingerprint

Tacrolimus
Prednisone
Allografts
Sirolimus
Kidney
Mycophenolic Acid
Graft Rejection
Feasibility Studies
Graft Survival
Immunosuppressive Agents
Proteinuria
Steroids
Calcineurin Inhibitors
Biopsy
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Chhabra, D., Alvarado, A., Dalal, P., Leventhal, J., Wang, C., Sustento-Reodica, N., ... Gallon, L. (2013). Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. American Journal of Transplantation, 13(11), 2902-2911. https://doi.org/10.1111/ajt.12437

Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. / Chhabra, D.; Alvarado, A.; Dalal, P.; Leventhal, J.; Wang, C.; Sustento-Reodica, N.; Najafian, N.; Skaro, A.; Levitsky, J.; Mas, Valeria; Gallon, L.

In: American Journal of Transplantation, Vol. 13, No. 11, 01.11.2013, p. 2902-2911.

Research output: Contribution to journalArticle

Chhabra, D, Alvarado, A, Dalal, P, Leventhal, J, Wang, C, Sustento-Reodica, N, Najafian, N, Skaro, A, Levitsky, J, Mas, V & Gallon, L 2013, 'Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen', American Journal of Transplantation, vol. 13, no. 11, pp. 2902-2911. https://doi.org/10.1111/ajt.12437
Chhabra, D. ; Alvarado, A. ; Dalal, P. ; Leventhal, J. ; Wang, C. ; Sustento-Reodica, N. ; Najafian, N. ; Skaro, A. ; Levitsky, J. ; Mas, Valeria ; Gallon, L. / Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. In: American Journal of Transplantation. 2013 ; Vol. 13, No. 11. pp. 2902-2911.
@article{1504b5ce61c34f27ba1558ce4c9ad872,
title = "Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen",
abstract = "Traditionally, chronic calcineurin inhibitor (CNI) nephrotoxicity has been considered to be one of the main nonimmune mechanisms causing chronic renal allograft dysfunction. CNI minimization and withdrawal strategies have yielded inconsistent results. Few studies address the feasibility of CNI elimination in a prednisone-free regimen. We report a prospective, randomized trial in 200 patients evaluating the impact on renal function and incidence of acute rejection after conversion from tacrolimus (Tac) to sirolimus (SRL). Patients with recent (<3 months) acute rejection episodes or with >0.5 g/day of proteinuria were excluded. All were induced with alemtuzumab, underwent rapid steroid elimination and were maintained on mycophenolate mofetil and Tac. At 12 months posttransplant, patients were randomized 2:1 to SRL (n = 123) or maintained on Tac (n = 64). Mean follow-up was 41.1 ± 15.8 months in the SRL group and 40.7 ± 14.4 months in the Tac group. Biopsy-proven acute rejection at 24 months postrandomization was similar between the groups. Patient survival, graft survival and estimated GFR were also not statistically different. Our study demonstrates that in a prednisone-free immunosuppressive regimen, conversion from Tac to SRL at 12 months posttransplantation is not associated with increased rates of acute rejection and graft loss. However, despite CNI elimination, renal allograft function is equally maintained in both groups.",
author = "D. Chhabra and A. Alvarado and P. Dalal and J. Leventhal and C. Wang and N. Sustento-Reodica and N. Najafian and A. Skaro and J. Levitsky and Valeria Mas and L. Gallon",
year = "2013",
month = "11",
day = "1",
doi = "10.1111/ajt.12437",
language = "English (US)",
volume = "13",
pages = "2902--2911",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen

AU - Chhabra, D.

AU - Alvarado, A.

AU - Dalal, P.

AU - Leventhal, J.

AU - Wang, C.

AU - Sustento-Reodica, N.

AU - Najafian, N.

AU - Skaro, A.

AU - Levitsky, J.

AU - Mas, Valeria

AU - Gallon, L.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Traditionally, chronic calcineurin inhibitor (CNI) nephrotoxicity has been considered to be one of the main nonimmune mechanisms causing chronic renal allograft dysfunction. CNI minimization and withdrawal strategies have yielded inconsistent results. Few studies address the feasibility of CNI elimination in a prednisone-free regimen. We report a prospective, randomized trial in 200 patients evaluating the impact on renal function and incidence of acute rejection after conversion from tacrolimus (Tac) to sirolimus (SRL). Patients with recent (<3 months) acute rejection episodes or with >0.5 g/day of proteinuria were excluded. All were induced with alemtuzumab, underwent rapid steroid elimination and were maintained on mycophenolate mofetil and Tac. At 12 months posttransplant, patients were randomized 2:1 to SRL (n = 123) or maintained on Tac (n = 64). Mean follow-up was 41.1 ± 15.8 months in the SRL group and 40.7 ± 14.4 months in the Tac group. Biopsy-proven acute rejection at 24 months postrandomization was similar between the groups. Patient survival, graft survival and estimated GFR were also not statistically different. Our study demonstrates that in a prednisone-free immunosuppressive regimen, conversion from Tac to SRL at 12 months posttransplantation is not associated with increased rates of acute rejection and graft loss. However, despite CNI elimination, renal allograft function is equally maintained in both groups.

AB - Traditionally, chronic calcineurin inhibitor (CNI) nephrotoxicity has been considered to be one of the main nonimmune mechanisms causing chronic renal allograft dysfunction. CNI minimization and withdrawal strategies have yielded inconsistent results. Few studies address the feasibility of CNI elimination in a prednisone-free regimen. We report a prospective, randomized trial in 200 patients evaluating the impact on renal function and incidence of acute rejection after conversion from tacrolimus (Tac) to sirolimus (SRL). Patients with recent (<3 months) acute rejection episodes or with >0.5 g/day of proteinuria were excluded. All were induced with alemtuzumab, underwent rapid steroid elimination and were maintained on mycophenolate mofetil and Tac. At 12 months posttransplant, patients were randomized 2:1 to SRL (n = 123) or maintained on Tac (n = 64). Mean follow-up was 41.1 ± 15.8 months in the SRL group and 40.7 ± 14.4 months in the Tac group. Biopsy-proven acute rejection at 24 months postrandomization was similar between the groups. Patient survival, graft survival and estimated GFR were also not statistically different. Our study demonstrates that in a prednisone-free immunosuppressive regimen, conversion from Tac to SRL at 12 months posttransplantation is not associated with increased rates of acute rejection and graft loss. However, despite CNI elimination, renal allograft function is equally maintained in both groups.

UR - http://www.scopus.com/inward/record.url?scp=84886800500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886800500&partnerID=8YFLogxK

U2 - 10.1111/ajt.12437

DO - 10.1111/ajt.12437

M3 - Article

VL - 13

SP - 2902

EP - 2911

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -